...
首页> 外文期刊>Journal of Clinical and Experimental Investigations >23-gauge pars plana vitrectomy surgery results of the cases with diabetic tractional retinal detachment
【24h】

23-gauge pars plana vitrectomy surgery results of the cases with diabetic tractional retinal detachment

机译:糖尿病性牵拉性视网膜脱离病例的23线标准尺玻璃体切除术手术结果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To evaluate the pars plana vitrectomy (PPV) surgery results of the patients with diabetic tractional retinal detachment (TRD). Methods: Two hundred ten eyes of 193 patients with diabetic TRD were enrolled to the study. Patients with TRD underwent 23-Gauge(G) PPV were reviewed retrospectively. All patients' preoperative and postoperative visual acuity changes, intraocular pressure changes, biomicroscopy, indirect ophthalmoscopy fundus examination, intraoperative and postoperative complications, intraoperative use of tamponade and postoperative period surgical notes were evaluated. Results: Ninety-five males (49.2%), 98 female (50.8%) of 193 patients were included to the study. Mean age was 56.01 ± 10.91 years during the surgery. The average postoperative follow-up period was 18.47 ± 14.06 (3-54) months. Ninety-seven eyes were performed preoperative intravitreal (IV) bevacizumab injection. Statistically significant increase in the final visual acuity compared to the controls were recorded at 1, 3, 6, 12, 24, 36. months. (p<0.001). Preoperative and postoperative 1st day, 1st month, 6th months, 12th months results were statistically significant according to intraocular pressure (p<0.001). While 201 (95%) cases achieved anatomical success, 165 (78.5%) cases were achieved functional success. Conclusion: PPV is very effective method in providing anatomical and functional outcomes in patients with diabetic TRD. Preoperative intravitreal bevacizumab application is an effective treatment method in reducing intraoperative and postoperative complications, and shorten the operation time.
机译:目的:评估糖尿病性牵引性视网膜脱离(TRD)患者的parsplana玻璃体切除术(PPV)的手术效果。方法:对193例糖尿病TRD患者的210只眼进行了研究。回顾性分析TRD患者接受了23-Gauge(G)PPV。评估所有患者的术前和术后视力变化,眼内压变化,生物显微镜,间接检眼镜眼底检查,术中和术后并发症,术中使用填塞剂和术后期手术记录。结果:193名患者中的九十五名男性(49.2%),98名女性(50.8%)被纳入研究。手术期间的平均年龄为56.01±10.91岁。术后平均随访时间为18.47±14.06(3-54)个月。术前进行玻璃体内(IV)贝伐单抗注射治疗共97只眼。与对照组相比,在1、3、6、12、24、36个月时记录了最终视力的统计学显着增加。 (p <0.001)。术前和术后第1天,第1个月,第6个月,第12个月的结果根据眼内压具有统计学意义(p <0.001)。在201例(95%)的病例中取得了解剖学上的成功,在165例(78.5%)的病例中获得了功能上的成功。结论:PPV是在糖尿病TRD患者中提供解剖学和功能结局的非常有效的方法。术前玻璃体内贝伐单抗的应用是减少术中和术后并发症,缩短手术时间的有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号